NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh

NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh

KKRX:950220
1,485.00
KRW
-9.00
(-0.60%)
-527.25EPS
8.82BMarket Cap
NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh
KRX:950220
(Korea Stock Exchange)

Recent

price

1,485.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
KRW
- -
- -
- -
- -
- -
43.2
0.8
37.72
Revenue per Share
-4,370
-9,205
-13,790
-15,310
-13,510
-10,365
-269.22
-527.25
Basic EPS, GAAP
-4,684.96
-9,065.01
-9,615.9
-11,375.32
-12,788.42
-10,296.21
-273.01
-601.08
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
35,021.27
25,453.72
41,093.31
30,277.33
18,928.47
10,534.77
8,830.32
8,407.92
Book Value per Share
32,804.65
23,498.28
39,421.98
28,619.47
17,368.86
8,900.91
6,918.43
5,395.12
Tangible Book Value per Share
3
3
4
4
4
4
118
46
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
170
95
1,754
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-23,497.6
-26,596.51
-1,200.62
Operating Margin (%)
781
988
1,873
2,802
3,210
3,673
2,498
2,475
Depreciation Expense
-14,198
-30,456
-52,482
-60,406
-53,405
-40,883
-31,796
-24,515
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-23,994.58
-33,531.39
-1,397.95
Profit Margin (%)
106,685
71,633
146,311
101,574
59,371
18,550
43,117
33,248
Working Capital
2,375
2,360
4,511
3,572
2,555
2,686
1,934
1,550
LT Debt
115,886
84,227
162,042
119,689
74,856
41,662
59,212
56,380
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-30.44
-42.62
-42.88
-54.9
-70.17
-63.04
-61.2
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8,558
9,153
9,731
LT Borrowings
- -
- -
- -
LT Finance Leases
1,934
1,757
1,550
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
27,526
17,535
8,824

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
63,804
60,595
51,417
Cash, Cash Equivalents & STI
60,822
57,831
47,275
Accounts Receivable, Net
32
391
1,344
Inventories
- -
- -
620
Total Current Liabilities
20,686
22,894
18,169
Payables & Accruals
- -
- -
- -
ST Debt
8,558
9,153
9,731
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
5.32%
42.13%
Free Cash Flow
- -
3.41%
-20.6%
Net Income, GAAP
- -
6.03%
-22.23%
Sales/Revenue/Turnover
- -
- -
-44.35%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
132
-920
170
2025
13
25
18
39
95
2026
527
1,170
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2,925
-2,495
-2,705
-2,168.67
-10,365
2025
-2,105
-9,210
-1,340
-63.92
-269.22
2026
-1,170
-59
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
NeoImmuneTech, Inc. is a biopharmaceutical firm in clinical development, dedicated to advancing T cell-focused immunotherapeutics. The company primarily concentrates on its leading asset, NT-I7 (efineptakin alfa), an investigational, long-acting human interleukin-7 designed to boost T cell numbers and function across various oncologic and infectious diseases. This innovative approach seeks to enhance the efficacy of existing treatments like checkpoint inhibitors and CAR-T cell therapies in solid tumors, hematologic malignancies, and conditions such as acute radiation syndrome and Progressive Multifocal Leukoencephalopathy. Recent developments include positive Phase 1b data combining NT-I7 with CAR-T for large B-cell lymphoma, demonstrating improved response rates and T-cell persistence, as well as an FDA IND approval for a combination trial with BCMA CAR-T therapy for multiple myeloma. Additionally, NT-I7 has received Orphan Drug Designations for conditions including glioblastoma multiforme, pancreatic cancer, and acute radiation syndrome. Established in 2014, NeoImmuneTech maintains its headquarters in Rockville, Maryland, with operations spanning both the U.S. and Korea.